Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis

NCT03966742 is registered in ClinicalTrials.gov with Rabin Medical Center as lead sponsor.

NCT NCT03966742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03966742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis
Lead sponsor
Rabin Medical Center
Phase
Phase 2
Overall status
Completed
Start date
October 11, 2018
Completion date
December 18, 2020
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive fibromatoses, desmoid, desmoid fibromatosis, desmoid fibromatosis of skin, desmoid neoplasm of chest wall, desmoid tumor caused by somatic mutation, fibromatosis desmoid